Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 113
Filtrar
3.
Int Forum Allergy Rhinol ; 10(2): 265-270, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-32086998

RESUMEN

BACKGROUND: Ketotifen is a second-generation noncompetitive H1-antihistamine and mast-cell stabilizer. It is commonly used to treat or prevent allergic conjunctivitis, asthma, chronic urticaria, anaphylaxis, mast-cell, and other allergic-type disorders. However, it has never been studied in aspirin-exacerbated respiratory disease (AERD), an aggressive phenotype of chronic rhinosinusitis with nasal polyps, where the mast cell plays a prominent role its pathogenesis. METHODS: Human sinonasal epithelial cells were grown at an air-liquid interface (ALI). Ketotifen powder was dissolved in saline to make 4 test solutions at 1.04, 2.08, 10.4, and 20.8 µg/mL. Control (saline) or ketotifen solution was added apically to ALI cultures from tissue of 5 unique patients, and ciliary beat frequency (CBF) changes were recorded. Lactate dehydrogenase was measured at 24 and 48 hours to estimate long-term cellular toxicity. RESULTS: Apical application of ketotifen at all concentrations was neither ciliotoxic nor ciliostimulatory, with no change in CBF over a period of 15 minutes after application. Cellular toxicity for all concentrations at 24 and 48 hours after application was <3% and <7%, respectively, that of lysed cultures. CONCLUSION: Topical application of ketotifen to an in vitro model of sinonasal epithelium is safe, as evaluated by CBF and lactate dehydrogenase. Ketotifen is neither ciliotoxic nor ciliostimulatory, and no long-term cellular toxicity was observed. Ketotifen may have promise as a topical nasal rinse in the treatment of AERD.


Asunto(s)
Antialérgicos/farmacología , Antagonistas de los Receptores Histamínicos H1/farmacología , Cetotifen/farmacología , Administración Tópica , Células Cultivadas , Cilios/efectos de los fármacos , Cilios/fisiología , Células Epiteliales/efectos de los fármacos , Células Epiteliales/fisiología , Humanos , L-Lactato Deshidrogenasa/metabolismo , Irrigación Terapéutica
4.
Neurotherapeutics ; 17(1): 218-234, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-31463682

RESUMEN

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by extensive inflammation, demyelination, axonal loss and gliosis. Evidence indicates that mast cells contribute to immunopathogenesis of both MS and experimental autoimmune encephalomyelitis (EAE), which is the most employed animal model to study this disease. Considering the inflammatory potential of mast cells, their presence at the CNS and their stabilization by certain drugs, we investigated the effect of ketotifen fumarate (Ket) on EAE development. EAE was induced in C57BL/6 mice by immunization with MOG35-55 and the animals were injected daily with Ket from the seventh to the 17th day after disease induction. This early intervention with Ket significantly reduced disease prevalence and severity. The protective effect was concomitant with less NLRP3 inflammasome activation, rebalanced oxidative stress and also reduced T cell infiltration at the CNS. Even though Ket administration did not alter mast cell percentage at the CNS, it decreased the local CPA3 and CMA1 mRNA expression that are enzymes typically produced by these cells. Evaluation of the CNS-barrier permeability indicated that Ket clearly restored the permeability levels of this barrier. Ket also triggered an evident lymphadenomegaly due to accumulation of T cells that produced higher levels of encephalitogenic cytokines in response to in vitro stimulation with MOG. Altogether these findings reinforce the concept that mast cells are particularly relevant in MS immunopathogenesis and that Ket, a known stabilizer of their activity, has the potential to be used in MS control.


Asunto(s)
Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Cetotifen/administración & dosificación , Estabilizadores de Mastocitos/administración & dosificación , Mastocitos/efectos de los fármacos , Esclerosis Múltiple/tratamiento farmacológico , Esclerosis Múltiple/inmunología , Animales , Encefalomielitis Autoinmune Experimental/inmunología , Femenino , Inflamasomas/efectos de los fármacos , Inflamasomas/inmunología , Inflamasomas/metabolismo , Mastocitos/inmunología , Ratones Endogámicos C57BL , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Estrés Oxidativo/efectos de los fármacos , Médula Espinal/efectos de los fármacos , Médula Espinal/inmunología , Médula Espinal/patología
5.
Asian J Androl ; 22(1): 112-117, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31115365

RESUMEN

The aim of this work was to study effects of ketotifen fumarate (KF) on prevention of tissue damage in testes of rats with experimental autoimmune orchitis (EAO) and on the contralateral testis in a model of prolonged testicular cord torsion (TCT). Rats with EAO or TCT were injected intraperitoneally once daily with KF or saline solution (vehicle group). Incidence and severity of testicular damage were evaluated by histopathology using an EAO score or a Johnsen score. Mast cells (MC) were identified by histochemistry and quantified. In EAO model, KF significantly reduced severity of histopathological testicular damage compared to rats in the vehicle group. KF also reduced the number of testicular MC compared to vehicle group. Similarly, in TCT model, multifocal damage of the contralateral testis was observed 30 days after testicular torsion characterized by sloughing of the germinal epithelium, seminiferous tubule atrophy, and interstitial edema. Focal signs of inflammation and fibrosis of seminiferous tubular walls were also observed. In contrast, sections of contralateral testis of rats injected with KF and killed 30 days after surgery showed normal histological features. A significant decrease in the number of MC was observed in rats treated with KF compared to untreated animals. In conclusion, we demonstrated that treatment with KF reduced testicular inflammatory process and MC infiltrates in both EAO and TCT models. The results suggest a promising treatment for infertile male patients with testicular pathologies associated with inflammation and germ cell loss.


Asunto(s)
Enfermedades Autoinmunes/patología , Epididimitis/patología , Antagonistas de los Receptores Histamínicos H1/farmacología , Cetotifen/farmacología , Mastocitos/efectos de los fármacos , Orquitis/patología , Torsión del Cordón Espermático/patología , Testículo/efectos de los fármacos , Animales , Enfermedades Autoinmunes/inmunología , Recuento de Células , Epidídimo/efectos de los fármacos , Epidídimo/inmunología , Epidídimo/patología , Epididimitis/inmunología , Hipersensibilidad Tardía , Inmunidad Celular/efectos de los fármacos , Masculino , Mastocitos/inmunología , Mastocitos/patología , Orquitis/inmunología , Ratas , Índice de Severidad de la Enfermedad , Torsión del Cordón Espermático/inmunología , Testículo/inmunología , Testículo/patología , Vacunación
6.
Exp Toxicol Pathol ; 65(3): 229-34, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21920722

RESUMEN

Tityus serrulatus venom (Tsv)-induced pulmonary edema can occur in severe envenomation and the mechanisms involved are not completely understood. Therefore, we studied the effect of pharmacological modulation of the mast cell activation and the histamine antagonism on airways edema (investigated by Evans blue dye extravasation) and measured 5-hydroxytryptamine (5-HT) concentration in bronchoalveolar lavage fluid (BALF) in rats envenomed by Tsv. Additionally, the in vitro effect of Tsv on mast cells was studied using histological method and 5-HT release from mesenteric and peritoneal mast cells. We found that i.v. injection of Tsv increase vascular permeability in trachea, upper and lower bronchi and in lung parenchyma. This was not affected by ketotifen, a mast cell "stabilizer," or by pretreatment with pyrilamine (histamine H1 receptor antagonist). Moreover, 5-HT was not found in BALF of envenomed rats. In vitro experiments showed that Tsv did not induce mast cell degranulation nor release of 5-HT by mesenteric or peritoneal mast cells, in sharp contrast to preparations challenged by a mast cell activator, compound 48/80. In conclusion, our results show that Tsv causes strong edema in rat airways which is independent of mast cell activation and show that mast cells are not directly activated by Tsv.


Asunto(s)
Permeabilidad Capilar/efectos de los fármacos , Mordeduras y Picaduras de Insectos/patología , Mastocitos/efectos de los fármacos , Sistema Respiratorio/efectos de los fármacos , Venenos de Escorpión/toxicidad , Animales , Líquido del Lavado Bronquioalveolar/citología , Degranulación de la Célula/efectos de los fármacos , Azul de Evans , Indicadores y Reactivos , Mordeduras y Picaduras de Insectos/fisiopatología , Cetotifen/farmacología , Masculino , Mastocitos/fisiología , Pirilamina/farmacología , Ratas , Ratas Wistar , Sistema Respiratorio/irrigación sanguínea , Escorpiones
7.
Nat Prod Res ; 26(23): 2168-75, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22239222

RESUMEN

From cultures of thermophilic soil fungus Humicola grisea var thermoidea, a δ-lactam derivative (3-(2-(4-hydroxyphenyl)-2-oxoethyl)-5,6-dihydropyridin-2(1H)-one) that displayed anti-allergic activity was isolated, which was predicted by in silico computational chemistry approaches. The in vitro anti-allergic activity was investigated by ß-hexosaminidase release assay in rat basophilic leukaemia RBL-2H3 cells. The δ-lactam derivative exhibited similar anti-allergic activity (IC(50) = 18.7 ± 6.7 µM) in comparison with ketotifen fumarate (IC(50) = 15.0 ± 1.3 µM) and stronger anti-allergic activity than azelastine (IC(50) = 32.0 µM). Also, the MTT cytotoxicity assay with RBL-2H3 cells showed that δ-lactam does not display cytotoxicity at concentrations lower than 50 µM. This study suggests that the δ-lactam derivative has the potential to be used as a lead compound in the development of anti-allergic drugs for clinical use in humans.


Asunto(s)
Antialérgicos/química , Antialérgicos/farmacología , Ascomicetos/química , Lactamas/química , Piridonas/química , Piridonas/farmacología , Animales , Degranulación de la Célula/efectos de los fármacos , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Simulación por Computador , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Concentración 50 Inhibidora , Cetotifen/farmacología , Espectroscopía de Resonancia Magnética , Estructura Molecular , Ftalazinas/farmacología , Ratas , Microbiología del Suelo , beta-N-Acetilhexosaminidasas/metabolismo
8.
Braz. j. pharm. sci ; 48(2): 211-216, Apr.-June 2012. graf, tab
Artículo en Inglés | LILACS | ID: lil-643013

RESUMEN

The purpose of the present study was to investigate the interaction between ketotifen fumarate and anhydrous theophylline in aqueous media of various pH (1.2 and 6.8). Using Job's continuous-variation analysis and Ardon's spectrophotomeric measurement methods, the values of the stability constants of theophylline with ketotifen were determined at a fixed temperature (37 ºC) at various pH. The stability constants, ranging between 5.66 and 9.92, were derived from Ardon's plot, indicating that comparatively stable complexes had formed as a result of an interaction between the drugs. However, following the interaction of theophylline with ketotifen, stability constants were <1 at gastric pH (1.2) and intestinal pH (6.8). Concurrent administration of ketotifen and theophylline could result in the formation of a stable complex and this is likely to reduce the therapeutic activities of both drugs.


O objetivo do presente estudo foi investigar a interação entre o fumarato de cetotifeno e a teofilina anidra em meios aquosos com vários pH (1,2 e 6,8). Utilizando a análise da variação contínua de Job e os métodos de medida espectrofotométrica de Ardon, os valores das constantes de estabilidade da teofilina com o cetotifeno foram determinados em temperatura fixa (37 oC) em vários pH. As constantes de estabilidade, variando entre 5,66 e 9,92 derivaram-se a partir do delineamento de Ardon, indicando, comparativamente, que complexos estáveis se formaram como resultado da interação entre os fármacos. Entretanto, seguindo a interação da teofilina com o cetotifeno, as constantes de estabilidade foram <1, em pH gástrico (1,2) e intestinal (8,8). A administração concomitante de cetotifeno e teofilina poderia resultar na formação de complexo estável, o que reduz a atividade terapêutica de ambos os fármacos.


Asunto(s)
Técnicas In Vitro/métodos , Cetotifen/análisis , Teofilina/análisis , Reactividad-Estabilidad
9.
Rev Med Inst Mex Seguro Soc ; 47(4): 399-404, 2009.
Artículo en Español | MEDLINE | ID: mdl-20553645

RESUMEN

OBJECTIVE: To compare the efficacy of olopatadine 0.1 % and ketotifen 0.025 % ophthalmic solutions in the treatment of allergic conjunctivitis. METHODS: Forty patients with allergic conjunctivitis were included in the study, they were randomized in two groups: G-I (n = 20) olopatadine 0.1 % and G-II (n = 20) ketotifen 0.025 %, both receiving one drop every 12 hours. We evaluated itching, burning, tearing, redness and chemosis previously and 30 minutes, one, two and four week after. RESULTS: Age G-I was 19.7 +/- 6.7 years; G-II, 21.05 +/- 8.3 years. When evaluating itching, olopatadine had a significant improvement at 30 minutes and after one week (p < 0.05). In the following weeks, the results were similar in both groups. Olopatadine showed significant improvement in burning at 30 minutes, one and two week (p < 0.05). Tearing significantly decreased at 30 minutes with olopatadine (p < 0.05). There was no difference in redness or chemosis improvement in both groups. CONCLUSIONS: In this study, olopatadine 0.1 % was more effective than topical ketotifen 0.025 % in improving itching, tearing and burning in allergic conjunctivitis patients.


Asunto(s)
Antialérgicos/uso terapéutico , Conjuntivitis Alérgica/tratamiento farmacológico , Dibenzoxepinas/uso terapéutico , Cetotifen/uso terapéutico , Femenino , Humanos , Masculino , Clorhidrato de Olopatadina , Adulto Joven
10.
Rev Alerg Mex ; 54(2): 66-9, 2007.
Artículo en Español | MEDLINE | ID: mdl-17542247

RESUMEN

This is a case report of a woman of 38 years old, studied and analyzed at the service of allergy and immunology with clinical manifestations of allergic rhinitis; studies of laboratory, cabinet and intradermal test were made to corroborate this diagnosis and the treatment with specific hyposensitization, oral antihistaminines and inhaled steroids was started. Two years later the patient referred urinary retention without important antecedents, so, a peripheral anticholinergic syndrome (PAS) was suspected, a urodynamic test study was carried out consisting in a uroflujometry, static and dynamic urethral profile, cystometry, flow pressure study and electromyography, which diagnosed low urinary obstruction (functional) and vesical sphincter pseudodysfunction, demonstrating the PAS associated with oral antihistamines.


Asunto(s)
Síntomas Afectivos/inducido químicamente , Antialérgicos/efectos adversos , Butirofenonas/efectos adversos , Caquexia/inducido químicamente , Antagonistas Colinérgicos/efectos adversos , Antagonistas de los Receptores Histamínicos H1 no Sedantes/efectos adversos , Antagonistas de los Receptores Histamínicos H1/efectos adversos , Cetotifen/efectos adversos , Loratadina/efectos adversos , Piperidinas/efectos adversos , Rinitis Alérgica Perenne/tratamiento farmacológico , Retención Urinaria/inducido químicamente , Adulto , Síntomas Afectivos/diagnóstico , Síntomas Afectivos/fisiopatología , Antialérgicos/administración & dosificación , Antialérgicos/uso terapéutico , Butirofenonas/administración & dosificación , Butirofenonas/uso terapéutico , Caquexia/diagnóstico , Caquexia/fisiopatología , Antagonistas Colinérgicos/administración & dosificación , Antagonistas Colinérgicos/uso terapéutico , Errores Diagnósticos , Quimioterapia Combinada , Femenino , Antagonistas de los Receptores Histamínicos H1/administración & dosificación , Antagonistas de los Receptores Histamínicos H1/farmacología , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Antagonistas de los Receptores Histamínicos H1 no Sedantes/administración & dosificación , Antagonistas de los Receptores Histamínicos H1 no Sedantes/uso terapéutico , Humanos , Cetotifen/administración & dosificación , Cetotifen/uso terapéutico , Loratadina/administración & dosificación , Loratadina/uso terapéutico , Furoato de Mometasona , Trastornos del Humor/diagnóstico , Piperidinas/administración & dosificación , Piperidinas/uso terapéutico , Pregnadienodioles/administración & dosificación , Pregnadienodioles/uso terapéutico , Receptores Muscarínicos/efectos de los fármacos , Receptores Muscarínicos/fisiología , Retención Urinaria/diagnóstico , Retención Urinaria/fisiopatología
11.
Arq. bras. oftalmol ; Arq. bras. oftalmol;69(6): 851-856, nov.-dez. 2006. tab, graf
Artículo en Portugués | LILACS | ID: lil-440423

RESUMEN

OBJETIVO: O objetivo desse estudo foi comparar as soluções oftálmicas de fumarato de cetotifeno 0,025 por cento e de cloridrato de olopatadina 0,1 por cento em pacientes portadores de ceratoconjuntivite primaveril. MÉTODOS: Avaliação realizada em um único centro, simples-cega, comparando-se paralelamente cetotifeno e olopatadina. As medicações foram avaliadas em 4 momentos (dias 1, 7, 14 e 21) por meio de tabelas de graduações padronizadas. A freqüência de eventos adversos foi a principal variável de segurança. RESULTADOS: Na avaliação da evolução do prurido ocular, ardor, lacrimejamento, hiperemia conjuntival, secreção e fotofobia observou-se que o uso tópico do cetotifeno proporcionou melhora significante deste sintoma em relação a olopatadina (p>0,05). Observou-se que a partir do 7° dia de tratamento os pacientes em uso da olopatadina tinham menos ardor, em relação aos que fizeram uso do cetotifeno, mas após o 21° dia essa relação inverteu. Na comparação da sensação de corpo estranho, papilas e pontos de Horner-Trantas evidenciou-se equivalência sem significância estatística. CONCLUSÃO: Concluímos que ambas são drogas equivalentes e atuaram de forma eficaz e segura na remissão dos sintomas relacionados à conjuntivite alérgica primaveril. Houve diferença a favor do cetotifeno (p<0,05) na melhora do prurido, lacrimejamento, hiperemia conjuntival, presença de secreção e fotofobia.


PURPOSE: To compare the topical use of 0.025 percent ketotifen fumarate and 0.1 percent olopatadine hydrochloride in the treatment of patients with vernal keratoconjunctivitis. METHODS: A study performed in one center, simple masked, parallel-group compared ketotifen and olopatadine. These patients were evaluated on four visits during the treatment (days 1, 7, 14 and 21), defined by ratings scores. Adverse events were the main variable of safety rating. RESULTS: On evaluating ocular itching, burning, tearing, conjunctival hyperemia, mucous discharge and photophobia, the ketotifen group showed a significant improvement of total signs and symptoms (p<0.05). Between the baseline and the 2nd visit, treatment with olopatadine resulted in decreased burning, but after the 4th visit, ketotifen was slightly better. Sand sensation, papillae and Horner-Trantas dots were not significantly different in both groups. CONCLUSION: Both drugs were efficient and safe relieving the main symptoms and signs of vernal keratoconjunctivitis. Between the same timepoints, there was a significant difference in favor of ketotifen-treated patients (p<0.05), showing improvement of itching, tearing, conjunctival hyperemia, mucous discharge and photophobia.


Asunto(s)
Humanos , Masculino , Femenino , Preescolar , Niño , Antialérgicos/efectos adversos , Conjuntivitis Alérgica/tratamiento farmacológico , Dibenzoxepinas/efectos adversos , Oftalmopatías/etiología , Cetotifen/efectos adversos , Administración Tópica , Antialérgicos/uso terapéutico , Distribución de Chi-Cuadrado , Dibenzoxepinas/uso terapéutico , Cetotifen/uso terapéutico , Soluciones Oftálmicas , Prurito/etiología , Estaciones del Año , Método Simple Ciego , Estadísticas no Paramétricas , Factores de Tiempo , Resultado del Tratamiento , Lágrimas/efectos de los fármacos
12.
GED gastroenterol. endosc. dig ; GED gastroenterol. endosc. dig;25(2): 58-62, mar-abr. 2006. ilus
Artículo en Portugués | LILACS | ID: lil-502163

RESUMEN

A gastroenterite eosinofílica (GE) é considerada uma doença pouco comum, com menos de 300 casos relatados na literatura. É caracterizada por infiltração eosinofílica das camadas da parede do tubo digestivo. A patogênese não é bem conhecida. Há algumas evidências da participação de fatores imunológicos ou alérgicos. Em geral, o prognóstico é favorável, embora a doença tenha caráter recorrente. Relata-se o caso de paciente, 21 anos, sexo masculino/ que apresentou quadro de dor abdominal, náusea, vômitos, emagrecimento e eliminação reduzida de flatos e fezes. Ao exame físico, foram observadas distensão abdominal, dor à palpação e ascite tensa. Os exames laboratoriais demonstraram eosinofilia no sangue periférico, variando de 15 a 60%. Exames parasitológicos de fezes seriados não mostraram ovos ou larvas. Ao estudo radiológico, identificaram-se espessamento da parede do intestino delgado e redução do lume. Infiltração eosinofílica da mucosa do cólon distal foi verificada pelo exame anatomopatológico. Com base nesses achados, o diagnóstico de GEfoi realizado e instituído o tratamento com prednisona, ocorrendo remissão da doença. Apesar de ser considerada doença rara e de causa ainda desconhecida, a GEdeve ser incluída no diagnóstico diferencial dos quadros de eosinofilia periférica com comprometimento do trato gastrintestinal (TGI).


Asunto(s)
Humanos , Masculino , Adulto , Ascitis/sangre , Gastroenteritis/tratamiento farmacológico , Síndrome Hipereosinofílico , Seudoobstrucción Intestinal , Biopsia , Colonoscopía , Cetotifen/uso terapéutico , Ciclofosfamida/uso terapéutico , Ciclosporina/uso terapéutico , Corticoesteroides/uso terapéutico , Examen Físico , Recurrencia , Signos y Síntomas , Tiabendazol/uso terapéutico
13.
Fertil Steril ; 85(1): 240-3, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16412767

RESUMEN

In an open, uncontrolled study, the effect of 12 weeks of daily administration of ketotifen, an antihistamine-like drug with a mast cell stabilizing effect, on the semen quality of 55 men with leukocytospermia and unexplained infertility was examined. After 4 weeks of treatment, white blood cell count dramatically diminished and was accompanied by a significant improvement in sperm motility. A significant increase of morphologically normal sperm cells was observed at 8 weeks of treatment, and these changes remained until at least 4 weeks after the end of treatment.


Asunto(s)
Antagonistas de los Receptores Histamínicos H1/administración & dosificación , Infertilidad Masculina/tratamiento farmacológico , Cetotifen/administración & dosificación , Motilidad Espermática/efectos de los fármacos , Espermatozoides/efectos de los fármacos , Adulto , Humanos , Infertilidad Masculina/patología , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Espermatozoides/citología
14.
Arq Bras Oftalmol ; 69(6): 851-6, 2006.
Artículo en Portugués | MEDLINE | ID: mdl-17273679

RESUMEN

PURPOSE: To compare the topical use of 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of patients with vernal keratoconjunctivitis. METHODS: A study performed in one center, simple masked, parallel-group compared ketotifen and olopatadine. These patients were evaluated on four visits during the treatment (days 1, 7, 14 and 21), defined by ratings scores. Adverse events were the main variable of safety rating. RESULTS: On evaluating ocular itching, burning, tearing, conjunctival hyperemia, mucous discharge and photophobia, the ketotifen group showed a significant improvement of total signs and symptoms (p<0.05). Between the baseline and the 2nd visit, treatment with olopatadine resulted in decreased burning, but after the 4th visit, ketotifen was slightly better. Sand sensation, papillae and Horner-Trantas dots were not significantly different in both groups. CONCLUSION: Both drugs were efficient and safe relieving the main symptoms and signs of vernal keratoconjunctivitis. Between the same timepoints, there was a significant difference in favor of ketotifen-treated patients (p<0.05), showing improvement of itching, tearing, conjunctival hyperemia, mucous discharge and photophobia.


Asunto(s)
Antialérgicos/uso terapéutico , Conjuntivitis Alérgica/tratamiento farmacológico , Dibenzoxepinas/uso terapéutico , Oftalmopatías/etiología , Cetotifen/uso terapéutico , Administración Tópica , Antialérgicos/efectos adversos , Distribución de Chi-Cuadrado , Niño , Preescolar , Dibenzoxepinas/efectos adversos , Femenino , Humanos , Cetotifen/efectos adversos , Masculino , Clorhidrato de Olopatadina , Soluciones Oftálmicas/efectos adversos , Soluciones Oftálmicas/uso terapéutico , Prurito/etiología , Estaciones del Año , Método Simple Ciego , Estadísticas no Paramétricas , Lágrimas/efectos de los fármacos , Factores de Tiempo , Resultado del Tratamiento
15.
Pharmacol Biochem Behav ; 78(4): 719-25, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15301927

RESUMEN

In the search for natural compounds useful against pruritus, alpha,beta-amyrins, the pentacyclic triterpenes isolated from the resin of popular medicinal plant Protium heptaphyllum were examined on scratching behavior induced by dextran T40 and compound 48/80 in mice. The animals were pretreated orally with alpha,beta-amyrins (50, 100 and 200 mg/kg) or cyproheptadine (10 mg/kg), an antagonist of histamine and serotonin receptors and 2 h later, they were given subcutaneous injections of dextran T40 (75 mg/kg) or compound 48/80 (3 mg/kg) into the rostral back, and scratching was quantified for 20 min. The scratching behavior induced by dextran T40 and compound 48/80 was significantly inhibited in mice pretreated with alpha,beta-amyrins (100 and 200 mg/kg) or cyproheptadine (10 mg/kg), In addition, the compound 48/80-elicited degranulation of rat peritoneal mast cells (ex vivo) was also markedly reduced in animals pretreated with alpha,beta-amyrins (100 mg/kg) or ketotifen (1 mg/kg), a known mast cell stabilizer. In the open-field test, alpha,beta-amyrins (100 and 200 mg/kg)-pretreated mice showed no impairment of spontaneous locomotion, suggesting that these triterpenoids possess no sedative activity that could account for suppression of scratching behavior. These results clearly indicate the antipruritic effect of alpha,beta-amyrins and suggest that this effect may be related to a stabilizing action on mast cell membrane.


Asunto(s)
Conducta Animal/efectos de los fármacos , Ácido Oleanólico/análogos & derivados , Ácido Oleanólico/farmacología , Prurito/tratamiento farmacológico , Prurito/psicología , Analgésicos Opioides/farmacología , Animales , Degranulación de la Célula/efectos de los fármacos , Ciproheptadina/farmacología , Dextranos , Endorfinas/fisiología , Femenino , Antagonistas de los Receptores Histamínicos H1/farmacología , Cetotifen/farmacología , Mastocitos/efectos de los fármacos , Mastocitos/ultraestructura , Ratones , Morfina/farmacología , Actividad Motora/efectos de los fármacos , Naloxona/farmacología , Antagonistas de Narcóticos/farmacología , Cavidad Peritoneal/citología , Prurito/inducido químicamente , Receptores Opioides mu/efectos de los fármacos , p-Metoxi-N-metilfenetilamina
16.
Rev Alerg Mex ; 51(6): 231-5, 2004.
Artículo en Español | MEDLINE | ID: mdl-15794416

RESUMEN

Eosinophilic colitis is a rare entity of unknown etiology characterized by diarrhea, abdominal pain, and gastrointestinal bleeding. Diagnosis includes histopathological infiltration of more than 20 eosinophils in colon. It is frequently associated with milk hypersensitivity and, less usual, with other foods and increased IgE. Histopthological appearance of eosinophil mediators has been observed in the gut. It is sometimes related to the degree of infiltration of eosinophils in the gut as well as to the disease severity. There is not an established treatment for this entity, although systemic steroids have been used with certain efficacy. However, there is a recurrence of the symptoms when the therapy stops, besides the well known side effects of the long-term use of steroids. Cromolyn inhibits mast cell degranulation and prevents liberation of mediators. It is successful in certain cases, specially the severe ones. However, it is not available for its use in our country. Ketotifen, as last resource in our patients with bad response to habitual treatment and restriction diet, was used. Although its use is controversial, we consider that stabilizing mast cell membrane with subsequent inhibition of degranulation and recruitment of eosinophils to sites of inflammation, would also restrain histamine liberation and blockage of H1 receptors, which would diminish local damage induced by eosinophils. Nonetheless ketotifen mechanism of action is unknown, our patients improved after treatment with this drug.


Asunto(s)
Colitis/tratamiento farmacológico , Eosinofilia/tratamiento farmacológico , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Cetotifen/uso terapéutico , Niño , Colitis/dietoterapia , Colitis/inmunología , Terapia Combinada , Nutrición Enteral , Eosinofilia/dietoterapia , Eosinofilia/inmunología , Femenino , Antagonistas de los Receptores Histamínicos H1/farmacología , Liberación de Histamina/efectos de los fármacos , Humanos , Hipersensibilidad Inmediata/complicaciones , Lactante , Alimentos Infantiles , Vólvulo Intestinal/cirugía , Cetotifen/farmacología , Masculino , Nutrición Parenteral , Complicaciones Posoperatorias , Píloro/cirugía
17.
Inflamm Res ; 52(5): 199-205, 2003 May.
Artículo en Inglés | MEDLINE | ID: mdl-12813624

RESUMEN

OBJECTIVE AND DESIGN: DhL, a lactone isolated from Artemisia douglasiana, prevents gastrointestinal damage elicited by necrosis-inducing agents and exhibits antiinflammatory action. This work examines the effect of DhL on compound 48/80-induced histamine and serotonin release in the isolated mouse jejunum, to determine whether DhL inhibits mediator release from mast cells at the enteric level. MATERIAL: Thirty jejuna from male Balb-c mice were used for the studies. TREATMENT: Samples were incubated sequentially in 9 test tubes containing RBS or 10 microg/ml compound 48/80 or 1.6 mmol/l + 10 microg/ml compound 48/80 at 37 degrees C for 90 minutes (10 min per tube). METHODS: Histamine and serotonin release studies, quantification of granulated mast cells, and evaluation of mast cell ultrastructure were carried out. Differences between groups were determined using analysis of variance followed by Tukey-Kramer multiple comparisons test. RESULTS: Compound 48/80 increased histamine and serotonin release by the tissue (141.95 +/- 62.58 pg/mg tissue vs basal 5.45 +/- 1.04, P<0.01 and 20.04 +/- 2.81 vs basal 9.24 +/- 1.56 ng/ mg tissue, P<0.01, respectively), decreased the number of granulated submucosal mast cells (0.077 +/- 0.0035 vs basal 0.14 +/- 0.015, P<0.05), and elicited evident granule ultrastructural changes. These effects were reduced by dehydroleucodine (19.51 +/- 7.88, P<0.01; 12.69 +/- 1, P<0.05 and 0.143 +/- 0.014, P<0.05, respectively). CONCLUSION: The lactone inhibits compound 48/80-induced histamine and serotonin release from mast cells in the isolated mouse jejunum.


Asunto(s)
Antiulcerosos/farmacología , Histamina/metabolismo , Yeyuno/metabolismo , Lactonas/farmacología , Mastocitos/metabolismo , Serotonina/metabolismo , Sesquiterpenos/farmacología , Animales , Antagonistas de los Receptores Histamínicos H1/farmacología , Procesamiento de Imagen Asistido por Computador , Técnicas In Vitro , Yeyuno/citología , Yeyuno/efectos de los fármacos , Cetotifen/farmacología , Masculino , Mastocitos/efectos de los fármacos , Mastocitos/ultraestructura , Ratones , Ratones Endogámicos BALB C , Microscopía Electrónica , Microscopía por Video , p-Metoxi-N-metilfenetilamina/farmacología
18.
Brain Behav Immun ; 17(1): 35-42, 2003 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-12615048

RESUMEN

In rats, the nematode Nippostrongylus brasiliensis induces an intestinal inflammation, but after the inflammation had resolved and the worm burden eliminated, morphological alterations of the intestinal wall, mainly consisting of mast cell hyperplasia and enteric nerve remodeling, persist for several weeks. Intestinal signals reaching the brain through the vagus nerve and involving neuropeptides such as CCK, play a role in the control of food intake. Our hypothesis was that neuroimmune alterations of the intestine may alter this control. This work was aimed to evaluate whether post-infection alterations of the intestinal wall may affect the satiety effects of CCK and further, the role of mast cells and their mediators, histamine and serotonin, in post-N. brasiliensis-infected rats. In basal conditions, food intake was not different in control and post-infected groups of rats. Post-infected rats were characterized by prolonged satiety effects of both CCK and histamine but not serotonin. The prolonged effect of CCK was reduced when mast cells were previously stabilized by ketotifen, which had no effect per se on food intake. No difference was observed in the increase of food intake induced by CCK-A and CCK-B receptor antagonists in both control and post-infected rats. Mast cell degranulation with compound 48/80 induced severe anorectic effects that lasted for less than 24h in post-infected rats and as long as 6 days in controls. Thus, in our experimental conditions, i.e., within 30-50 days post-N. brasiliensis infection, we observed an enhancement of the anorectic effect of exogenous CCK involving mast cell degranulation and histamine.


Asunto(s)
Colecistoquinina/farmacología , Nippostrongylus , Respuesta de Saciedad/efectos de los fármacos , Infecciones por Strongylida/fisiopatología , Animales , Benzodiazepinonas/farmacología , Degranulación de la Célula/fisiología , Devazepida/farmacología , Ingestión de Alimentos/efectos de los fármacos , Histamina/farmacología , Antagonistas de los Receptores Histamínicos H1/farmacología , Antagonistas de Hormonas/farmacología , Cetotifen/farmacología , Masculino , Mastocitos/fisiología , Compuestos de Fenilurea/farmacología , Ratas , Ratas Wistar , Receptores de Colecistoquinina/antagonistas & inhibidores , Serotonina/farmacología
19.
BMC Ophthalmol ; 3: 2, 2003 Jan 06.
Artículo en Inglés | MEDLINE | ID: mdl-12515585

RESUMEN

BACKGROUND: The efficacy and safety of ketotifen eye drop treatment in allergic conjunctivitis (AC) management is perfectly known by several studies, but the mechanism of action at the biochemical levels is poorly understood so we decided to perform an open, uncontrolled study in order to investigate the effect of the topical administration of ketotifen fumarate 0.05% on biochemical markers of inflammation on conjunctival cells in patients with AC. METHODS: Nineteen patients with symptoms and signs of AC (itching, discharge, burning, redness, increase in the watery discharge, swelling and follicles) and with a history of allergy were prescribed with two daily instillation of one drop of eyewash ketotifen fumarate 0,05% in both eyes during thirty days. They were studied by measuring clinical and immunologic parameters. RESULTS: Ketotifen fumarate treatment significantly reduced the total symptoms and signs score for each patient as well as each symptoms and signs at all time points compared with day 0 (p < 0.0001 and p < 0.016, respectively). Although the percentage of HLA-DR+ epithelial cells diminished only in 58% of patients, the numbers of CD29+ and eotaxin+ epithelial cells dropped significantly in 68% and 73 % of them (p < 0.0062 and <0.0082, respectively) as a consequence of the treatment. In 9 out of 19 patients a simultaneous decrease in the percentage of epithelial cells positive for CD29 and eotaxin was observed. CONCLUSION: Ketotifen besides the well-known effect in reducing signs and symptoms of AC significantly diminished production of eotaxin and expression of CD29 by epithelial cells in patients with seasonal AC.


Asunto(s)
Quimiocinas CC/metabolismo , Conjuntivitis Alérgica/tratamiento farmacológico , Antígenos HLA-DR/metabolismo , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Integrina beta1/metabolismo , Cetotifen/uso terapéutico , Administración Tópica , Adolescente , Adulto , Biomarcadores/análisis , Quimiocina CCL11 , Factores Quimiotácticos Eosinófilos/metabolismo , Niño , Conjuntiva/efectos de los fármacos , Conjuntiva/metabolismo , Conjuntivitis Alérgica/metabolismo , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Femenino , Antagonistas de los Receptores Histamínicos H1/administración & dosificación , Humanos , Cetotifen/administración & dosificación , Masculino , Persona de Mediana Edad , Soluciones Oftálmicas
20.
Medicentro ; 7(2)2003. tab, graf
Artículo en Español | CUMED | ID: cum-23338

RESUMEN

El asma bronquial es la enfermedad crónica no transmisible que constituye en nuestro país la principal causa de ingresos hospitalarios. Los medicamentos empleados para su control son varios, y para el Ministerio de Salud Pública es una prioridad lograr su uso racional. Las altas tasas de prescripción del ketotifeno (tabletas 1 mg) en la provincia de Villa Clara representan un problema para los directivos de salud en el territorio, por lo que se realizó una investigación en servicios de salud de tipo descriptiva sobre el comportamiento de la prescripción de este fármaco en el área de salud correspondiente al Policlínico Docente "Santa Clara", en la ciudad del mismo nombre, durante el año 2000. Se revisaron los certificados médicos controlados en las farmacias pertenecientes a dicha área. Fue encuestado el 30 por ciento (muestreo estratificado aleatorio) de los pacientes mayores de 15 años de edad que consumen el medicamento, así como el personal de salud responsable de la prescripción del mismo, y se halló que la indicación-utilización del ketotifeno tabletas no fue recomendable. Un alto por ciento de indicaciones se relacionó con el tratamiento del asma bronquial, a pesar de no haberse demostrado la eficacia del mismo en esta enfermedad. Se comprobó un nivel de competencia no adecuado del personal médico en relación con el uso del medicamento, y se recomendó investigar las causas de esta insuficiencia por parte del personal médico con relación al ketotifeno tabletas, para aplicar medidas específicas al respecto(AU)


Asunto(s)
Humanos , Cetotifen/uso terapéutico , Asma/tratamiento farmacológico , Atención Primaria de Salud
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA